ReviewFrontiers in genetics2014
Pharmacogenomics in oncology care.
Review in Frontiers in genetics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Healthcare professionals' and consumers' knowledge, attitudes, perspectives, and education needs in oncology pharmacogenomics: A systematic review.Clinical and translational science · 2023Pooled it
- Clinically actionable pharmacogenomic variants for anticancer therapy in Nigeria: first comprehensive variant profiling in underrepresented Nigerian cohorts.BMC medical genomics · 2026Article
- The Role of Pharmacogenetic-Based Pharmacokinetic Analysis in Precise Breast Cancer Treatment.Pharmaceutics · 2024Review
- Emerging trends in pharmacogenomics: from common variant associations toward comprehensive genomic profiling.Human genomics · 2023Article
- Pharmacogenomics in clinical trials: an overview.Frontiers in pharmacology · 2023Article
- The Role of Pharmacogenomics in Opioid Prescribing.Current treatment options in oncology · 2022Review
- Quantitative Proteomics in Translational Absorption, Distribution, Metabolism, and Excretion and Precision Medicine.Pharmacological reviews · 2022Review
- Increasing inclusivity in precision medicine research: Views of deaf and hard of hearing individuals.Genetics in medicine : official journal of the American College of Medical Genetics · 2022Article
- Understanding of Immune Escape Mechanisms and Advances in Cancer Immunotherapy.Journal of oncology · 2022Review
- Editorial: How pharmacogenomics, epigenetics, and data analysis could improve anticancer treatment?Frontiers in pharmacology · 2022Article
- Pharmacogenomic biomarker information differences between drug labels in the United States and Hungary: implementation from medical practitioner view.The pharmacogenomics journal · 2020Article
- Added Value of Clinical Sequencing: WGS-Based Profiling of Pharmacogenes.International journal of molecular sciences · 2020Article
- Germline variants in cancer therapy.Cancer drug resistance (Alhambra, Calif.) · 2019Review
- Pharmacogenetic and pharmacogenomic discovery strategies.Cancer drug resistance (Alhambra, Calif.) · 2019Review
- Pharmacogenetics: An Important Part of Drug Development with A Focus on Its Application.International journal of biomedical investigation · 2018Article
- Pharmacoresistant Severe Mental Health Disorders in Children and Adolescents: Functional Abnormalities of Cytochrome P450 2D6.Frontiers in psychiatry · 2018Article
- Precision medicine and pharmacogenetics: what does oncology have that addiction medicine does not?Addiction (Abingdon, England) · 2017Review
- Evidence and resources to implement pharmacogenetic knowledge for precision medicine.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2016Review
- Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine.Genomics, proteomics & bioinformatics · 2016Review
- Genetics of Lupus Nephritis: Clinical Implications.Seminars in nephrology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer pharmacogenomics have contributed a number of important discoveries to current cancer treatment, changing the paradigm of treatment decisions. Both somatic and germline mutations are utilized to better understand the underlying biology of cancer growth and treatment response. The level of evidence required to fully translate pharmacogenomic discoveries into the clinic has relied heavily on randomized control trials. In this review, the use of observational studies, as well as, the use of adaptive trials and next generation sequencing to develop the required level of evidence for clinical implementation are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.